123 related articles for article (PubMed ID: 10327033)
21. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
Cunningham D; Zalcberg J; Maroun J; James R; Clarke S; Maughan TS; Vincent M; Schulz J; González Barón M; Facchini T
Eur J Cancer; 2002 Mar; 38(4):478-86. PubMed ID: 11872339
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
24. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
Lloyd Jones M; Hummel S; Bansback N; Orr B; Seymour M
Health Technol Assess; 2001; 5(25):1-128. PubMed ID: 11990245
[No Abstract] [Full Text] [Related]
25. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
Sato A; Kurihara M; Horikoshi N; Aiba K; Kikkawa N; Shirouzu K; Mitachi Y; Sakata Y; Wakui A
Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
[TBL] [Abstract][Full Text] [Related]
26. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.
Zalcberg J; Kerr D; Seymour L; Palmer M
Eur J Cancer; 1998 Nov; 34(12):1871-5. PubMed ID: 10023308
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
28. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
29. Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
Farrugia DC; Norman AR; Cunningham D
Eur J Cancer; 1998 Jun; 34(7):987-91. PubMed ID: 9849444
[TBL] [Abstract][Full Text] [Related]
30. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.
Matasar MJ; Sundararajan V; Grann VR; Neugut AI
Drugs Aging; 2004; 21(2):113-33. PubMed ID: 14960128
[TBL] [Abstract][Full Text] [Related]
31. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
Popov I; Carrato A; Sobrero A; Vincent M; Kerr D; Labianca R; Raffaele Bianco A; El-Serafi M; Bedenne L; Paillot B; Mini E; Sanches E; Welch J; Collette L; Praet M; Wils J
Eur J Cancer; 2008 Oct; 44(15):2204-11. PubMed ID: 18707870
[TBL] [Abstract][Full Text] [Related]
32. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
33. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
[TBL] [Abstract][Full Text] [Related]
35. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Franken MD; Koopman M; van Oijen MG
Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
[No Abstract] [Full Text] [Related]
39. 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies.
Judson IR
Anticancer Drugs; 1997 Aug; 8 Suppl 2():S5-9. PubMed ID: 9376637
[TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Tappenden P; Jones R; Paisley S; Carroll C
Eur J Cancer; 2007 Nov; 43(17):2487-94. PubMed ID: 17910914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
